Persistent parvovirus B19 related anemia of seven years' duration in an HIV-infected patient: Complete remission associated with highly active antiretroviral therapy
E. Mylonakis et al., Persistent parvovirus B19 related anemia of seven years' duration in an HIV-infected patient: Complete remission associated with highly active antiretroviral therapy, AM J HEMAT, 60(2), 1999, pp. 164-166
A human immunodeficiency virus (HIV)-infected individual was first diagnose
d with red blood cell aplasia due to B19 parvovirus infection in late 1989.
Over the subsequent seven-year period, he received a Petal of 119 units of
red blood cells (RBCs) and intravenous immunoglobulin every 2-3 weeks. In
1996 combination antiretroviral treatment with a protease inhibitor was ini
tiated. He received four more units during the following two months and the
n required no more transfusions for the subsequent 24 months of follow-up.
His CD4 count progressively increased and DNA polymerase chain reaction for
parvovirus B19 became undetectable. Aggressive antiretroviral treatment ma
y effectively diminish transfusion requirements among HIV-infected Individu
als with pure RBC aplasia resulting from parvovirus B19 infection. (C) 1999
Wiley-Liss, Inc.